JP2023544249A5 - - Google Patents

Info

Publication number
JP2023544249A5
JP2023544249A5 JP2023515723A JP2023515723A JP2023544249A5 JP 2023544249 A5 JP2023544249 A5 JP 2023544249A5 JP 2023515723 A JP2023515723 A JP 2023515723A JP 2023515723 A JP2023515723 A JP 2023515723A JP 2023544249 A5 JP2023544249 A5 JP 2023544249A5
Authority
JP
Japan
Prior art keywords
day
composition according
ribitol
disorder
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544249A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/049677 external-priority patent/WO2022056137A1/en
Publication of JP2023544249A publication Critical patent/JP2023544249A/ja
Publication of JP2023544249A5 publication Critical patent/JP2023544249A5/ja
Pending legal-status Critical Current

Links

JP2023515723A 2020-09-10 2021-09-09 リビトール治療 Pending JP2023544249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
US63/076,761 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (2)

Publication Number Publication Date
JP2023544249A JP2023544249A (ja) 2023-10-23
JP2023544249A5 true JP2023544249A5 (https=) 2024-09-11

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515723A Pending JP2023544249A (ja) 2020-09-10 2021-09-09 リビトール治療

Country Status (10)

Country Link
US (1) US20230364118A1 (https=)
EP (1) EP4210708A4 (https=)
JP (1) JP2023544249A (https=)
KR (1) KR20230069941A (https=)
CN (1) CN117355310A (https=)
AU (1) AU2021338706A1 (https=)
CA (1) CA3191582A1 (https=)
IL (1) IL301088A (https=)
MX (1) MX2023001881A (https=)
WO (1) WO2022056137A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
AU2020283556A1 (en) 2019-05-28 2022-01-06 The Charlotte-Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods of making ribitol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
US20200061092A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Similar Documents

Publication Publication Date Title
JP2024074963A5 (https=)
Reimherr et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
RU2707089C2 (ru) Комбинированная композиция
JPH0222229A (ja) 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤
JP2001513487A5 (https=)
JP2023544249A5 (https=)
JP2023531679A5 (https=)
WO2024160030A1 (zh) 一种组合物及其在制备治疗神经性疼痛药物中的应用
JP2022553888A5 (https=)
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
EA004474B1 (ru) Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола
RU2192252C2 (ru) Применение прамипексола в лечении синдрома усталых ног
JP2004091473A (ja) 色素沈着改善治療薬
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
JP2021530568A5 (https=)
Bolte et al. Case of fluoxetine-induced remission of Raynaud's phenomenon—a case report
JP2025522146A5 (https=)
RU2003100081A (ru) Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии
JP2024531799A5 (https=)
JP2022546042A5 (https=)
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
EP2340026B1 (en) A deproteinised calf blood preparation for use in prevention or treatment of diabetic peripheral polyneuropathy
Han Safety of Topical Calcineurin Inhibitors for Hailey-Hailey Disease
JP2018177773A (ja) 医薬
JP2024518455A5 (https=)